casodex 150 mg filmovertrukne tabletter
laboratoires juvisé pharmaceuticals - bicalutamid - filmovertrukne tabletter - 150 mg
levact 2,5 mg/ml pulver til koncentrat til infusionsvæske, opløsning
astellas pharma gmbh - bendamustinhydrochlorid - pulver til koncentrat til infusionsvæske, opløsning - 2,5 mg/ml
klomentan comp 50 mg+12,5 mg filmovertrukne tabletter
aristo pharma gmbh - hydrochlorthiazid, losartankalium - filmovertrukne tabletter - 50 mg+12,5 mg
ulcerex 40 mg enterokapsler, hårde
aristo pharma gmbh - esomeprazolmagnesiumdihydrat - enterokapsler, hårde - 40 mg
memantine merz
merz pharmaceuticals gmbh - memantinhydrochlorid - alzheimers sygdom - andre anti-demensmidler - behandling af patienter med moderat til svær alzheimers sygdom.
pregabalin mylan pharma
mylan s.a.s. - pregabalin - anxiety disorders; neuralgia; epilepsy - antiepileptika, - epilepsypregabalin mylan pharma er indiceret som adjuverende behandling til voksne med partielle anfald med eller uden sekundær generalisering. generaliseret angst disorderpregabalin mylan pharma er indiceret til behandling af generaliseret angst (gad) hos voksne.
lactulose "mip" 650 mg/ml oral opløsning
mip pharma gmbh - lactuloseopløsning - oral opløsning - 650 mg/ml
myrlosar comp 50+12,5 mg filmovertrukne tabletter
aristo pharma gmbh - hydrochlorthiazid, losartankalium - filmovertrukne tabletter - 50+12,5 mg
pirfenidone axunio (previously pirfenidone aet)
axunio pharma gmbh - pirfenidon - idiopatisk lungefibrose - immunosuppressiva - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiske - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).